0.75 CME Credits. This webinar discusses ADHD and its varied presentations, co-occurring issues, and the importance of accurate assessment for effective treatment.
0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.
0.25 CME Credits. Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.
0.50 CME Credits. Learn how to address depression in older adults, identify the risk factors and triggers, distinguish depression from normal aging, and explore effective treatment options.
A teen is using substances—how do you decide what kind of treatment makes sense? Outpatient therapy? A more structured program? We’re breaking it down.
Imagine turning 18 and suddenly being responsible for every major life decision. Yikes. That includes medical, financial, and personal, without guidance. For many young adults with developmental disabilities, these transitions can be overwhelming. How can clinicians and families provide the right level of support while respecting autonomy or at least encouraging it? That's what we're exploring today.
Many families struggle to find OCD treatment for their children. Specialty-trained therapists are limited, and wait lists are usually long. Online therapy is an option, but how well does it work? Today, we discuss a study that examines online cognitive behavioral therapy with exposure and response prevention for kids with OCD.
She's slower than her colleagues. Always the last to leave meetings. Takes forever to finish tasks. Then you ask the right question: "Do you have any repetitive behaviors or thoughts that feel hard to control?" Suddenly, everything clicks.
GLP-1 agonists may get the spotlight—but they’re not the only option. Many patients can’t afford them, don’t want the side effects, or prefer to stick with psychiatric meds they already know.
When patients are acutely psychotic, manic, or suicidal, our impulse is to fine tune the meds. But a few years ago—while working primarily inpatient—I realized I was leaning too heavily on medication. My patients needed more.
I just read a Lilly-sponsored CME on Medscape featuring Dr. Malaz Boustani—a respected geriatrician doing critical work with underserved communities. But this isn't just education—it's marketing for Lilly’s anti-amyloid drug Donabemab.